USANA Health Sciences Inc. - Q2 2007 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2007, and the six months ended June 30, 2007. USANA Health Sciences, Inc. develops and distributes nutritional and personal care products through a network marketing system. The company operates in two primary geographic segments: North America and Asia Pacific. Notably, the company is in the process of discontinuing its third-party contract manufacturing business, classifying these operations as discontinued.
Critical Filing Status: The financial statements included in this report have not been reviewed by an independent public accountant. The company's auditor, Grant Thornton LLP, resigned on July 10, 2007, prior to completing the required review. Consequently, the CEO and CFO certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act are omitted until a new auditor completes the review.
Key Financial Metrics
| Metric (in thousands) | Q2 2007 | Q2 2006 | 6-Month 2007 | 6-Month 2006 |
|---|---|---|---|---|
| Net Sales | $107,542 | $89,694 | $208,220 | $175,078 |
| Gross Profit | $85,099 | $70,375 | $165,191 | $137,381 |
| Gross Margin | 79.1% | 78.5% | 79.3% | 78.5% |
| Net Earnings | $11,314 | $10,344 | $23,000 | $19,904 |
| Diluted EPS | $0.66 | $0.55 | $1.29 | $1.05 |
| Cash & Equivalents | $9,876 | $27,029 (Dec 2006) | $9,876 | $27,029 (Dec 2006) |
| Operating Cash Flow (6mo) | $32,599 | $30,238 | ||
| Line of Credit Outstanding | $34,515 | $0 | $34,515 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19.9% year-over-year in Q2 2007. Growth was driven by a 25.4% increase in active Associates (to 178,000) and the launch of operations in Malaysia, which contributed $4.5 million in Q2 sales.
- Profitability: Income from continuing operations rose 8.0% in Q2. Gross margins improved due to lower freight costs and reduced inventory scrap.
- Liquidity Shift: Cash and cash equivalents dropped significantly from $27.0 million (Dec 2006) to $9.9 million (June 2007). This decrease was primarily due to $73.0 million in share repurchases and $14.3 million in capital expenditures (facility expansions in Utah and Australia).
- Debt Utilization: The company drew $34.5 million on its $40 million line of credit to fund share buybacks and capital projects, compared to zero utilization in the prior year.
- Discontinued Operations: The company recorded a net loss of $93,000 from discontinued operations (third-party contract manufacturing) in Q2 2007, compared to $214,000 in Q2 2006. Assets related to this segment are held for sale.
Guidance, Outlook, and Risks
- Q3 2007 Guidance: Management expects consolidated net sales between $105 million and $107 million, representing 12-14% year-over-year growth. Diluted EPS from continuing operations is expected to be between $0.65 and $0.67.
- Tax Rate: The company anticipates an effective tax rate of 37.0% for the full year 2007, an increase from 35.3% in 2006, due to the phase-out of the Extraterritorial Income Exclusion.
- Auditor Resignation Risk: The resignation of Grant Thornton LLP creates uncertainty regarding the timely filing of future reports and the company's ability to use short-form registration statements (Forms S-2 and S-3) until the deficiency is cured.
- Legal Proceedings: The company is facing four class-action lawsuits alleging securities law violations and defamation claims related to allegations made by Barry Minkow. Additionally, the SEC has initiated an informal inquiry. Management believes these claims are without merit.
- Capital Expenditures: The company is expanding its corporate headquarters (estimated total cost $20 million) and fitting out a new facility in Australia (estimated additional cost $5.8 million).
Investor Verification Checklist
- Auditor Status: Verify the appointment of a new independent auditor and the subsequent filing of an amended 10-Q with reviewed financial statements.
- Liquidity Position: Monitor the company's cash burn rate relative to its $34.5 million line of credit drawdown and the remaining $5.5 million availability.
- Legal Outcomes: Track the status of the SEC informal inquiry and the four pending class-action lawsuits, as adverse rulings could impact financial condition.
- Share Repurchase Plan: Confirm the execution of the newly authorized $50 million share repurchase program announced in July 2007.
- Discontinued Operations: Verify the closing of the sale of the third-party contract manufacturing assets and the finalization of the impairment loss.